unknown
Stage
About
Apim Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting peptide therapeutics to disrupt cellular stress responses and overcome cancer treatment resistance, with its lead candidate ATX-101 currently in clinical trials.
Explore Apim Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.